How Much Does Talquetamab Cost?

For patients with relapsed or refractory multiple myeloma, Talquetamab has emerged as one of the most promising new treatment options. Many patients who have already received multiple lines of therapy, including stem cell transplantation, anti-CD38 antibodies, immunomodulatory drugs, and proteasome inhibitors, are now asking the same question:

How much does Talquetamab cost, and where can I receive treatment?

The answer depends on the country, the healthcare system, insurance coverage, and whether the treatment is available through a public reimbursement program.

Quick Overview: Talquetamab Availability and Cost Considerations

Swipe table to see all columns

Important: Talquetamab pricing changes frequently and depends on body weight, dosing schedule, insurance coverage, and local reimbursement policies. Patients should always request an individualized estimate from the treating hospital.

What Is Talquetamab?

Talquetamab (brand name Talvey®) is a bispecific antibody used to treat relapsed or refractory multiple myeloma.
Unlike traditional chemotherapy, Talquetamab works by helping the patient's immune system recognize and attack myeloma cells. It targets a protein called GPRC5D found on myeloma cells while simultaneously binding to CD3 on T-cells. This brings immune cells directly into contact with the cancer cells, helping destroy them.

Talquetamab belongs to a new generation of immunotherapies that have transformed treatment options for patients whose disease has returned after multiple previous therapies.

One of its major advantages is that it is an "off-the-shelf" treatment. Unlike CAR-T therapy, Talquetamab does not require collection and manufacturing of the patient's own cells before treatment can begin.

When Is Talquetamab Used?

Talquetamab is approved for adults with relapsed or refractory multiple myeloma who have already received several previous treatments.
Typically, patients have already been treated with:

• A proteasome inhibitor such as bortezomib (Velcade) or carfilzomib (Kyprolis)
• An immunomodulatory drug such as lenalidomide (Revlimid) or pomalidomide (Pomalyst)
• An anti-CD38 antibody such as daratumumab (Darzalex) or isatuximab (Sarclisa)

Patients receiving Talquetamab have often exhausted many standard treatment options and are looking for effective alternatives before or after CAR-T therapy.

Clinical studies have shown response rates of approximately 70% in heavily pretreated patients, making Talquetamab one of the most exciting recent developments in multiple myeloma treatment.

Talquetamab vs CAR-T Therapy

Patients frequently compare Talquetamab with CAR-T therapy because both are advanced immunotherapies used for relapsed multiple myeloma.

Advantages of Talquetamab

• Treatment can begin quickly
• No need for T-cell collection
• No manufacturing waiting period
• Available as an off-the-shelf therapy
• Suitable for some patients who may not qualify for CAR-T therapy
• Can be administered repeatedly over time

Advantages of CAR-T Therapy

• May provide deeper and longer-lasting remissions in some patients
• Requires only a single infusion rather than ongoing treatment
• Growing long-term follow-up data
• May achieve minimal residual disease (MRD) negativity in some patients

Which Is Better?

There is no single answer.
Some patients may benefit more from Talquetamab, while others may be better candidates for CAR-T therapy. The decision depends on:

• Previous treatments
• Disease characteristics
• General health and performance status
• Availability of treatment
• Waiting times
• Physician recommendation

An experienced myeloma specialist should evaluate each case individually.

Cost Considerations

Talquetamab is a highly specialized biologic therapy and can be expensive.
In countries where the drug is not fully reimbursed, treatment costs may reach tens of thousands of dollars per month.
The overall cost may include:

• The medication itself
• Hospital visits
• Blood tests and laboratory monitoring
• Physician consultations
• Imaging studies
• Management of treatment-related side effects
• Possible hospitalization during treatment initiation

Because dosing depends on body weight and treatment schedule, the final cost can vary significantly from patient to patient.
Patients should obtain a personalized estimate from the treating center.

Availability in Different Countries

Talquetamab has received regulatory approval in several major healthcare markets, including:

• United States
• European Union countries
• United Kingdom
• Canada
• Australia
• Israel
• Additional countries that continue to adopt new myeloma therapies

However, approval does not always guarantee immediate access.
Some healthcare systems may have reimbursement restrictions, waiting lists, or eligibility criteria that affect treatment availability.
As a result, some patients explore treatment options abroad.

Conclusion

Talquetamab represents an important new option for patients with relapsed or refractory multiple myeloma.
Its ability to provide rapid access to advanced immunotherapy without the manufacturing delays associated with CAR-T therapy has made it an increasingly valuable treatment option worldwide.
Because availability, reimbursement, and pricing vary substantially between countries, patients should obtain individualized information from experienced myeloma specialists before making treatment decisions.

Publication date: June 2026

Sources
1. FDA – Talquetamab-tgvs (Talvey) Approval.
2. European Medicines Agency (EMA) – Talvey.
3. International Myeloma Foundation – Talvey (Talquetamab).
4. Janssen Medical Information – MonumenTAL-1 Study.
5. National Cancer Institute (NCI) Dictionary.